Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer's Disease Subgroup
2025 Objective: Advance Zervimesine into Late-stage Trials for DLB and Alzheimer's Disease
Management will Review Results at 8:00 a.m. ET on Live Webcast and Conference Call
PURCHASE, N.Y., March 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the 'Company' or 'Cognition'), today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.
Data readouts in 2024 from the Company's Phase 2 studies in mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB) support the potential of zervimesine (also CT1812) in these patient populations. The Company reprioritized its clinical focus in 2025, concluding enrollment in the Phase 2 dry AMD clinical study in order to devote resources to support the planned registrational programs for Alzheimer's and DLB, and extend the cash runway into the fourth quarter of 2025.
Next steps for zervimesine include end-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) to align on plans for Phase 3 clinical protocols for both indications. The company plans to request separate end-of-Phase 2 meetings for Alzheimer's disease and DLB. That process is expected to start in early second quarter of 2025. The FDA typically responds to a request within two weeks.
Lisa Ricciardi, Cognition's president and CEO, added, 'Zervimesine delivered positive clinical data during 2024 from two key Phase 2 studies: the SHIMMER study in DLB and the SHINE study in Alzheimer's disease. These results show the value that zervimesine holds as we advance towards Phase 3 clinical trials. Looking ahead, we will meet with the FDA on plans to start Phase 3 studies in Alzheimer's disease and DLB. In parallel, we are actively evaluating options to fund our clinical trials, including potential partnering opportunities with pharmaceutical companies.'
2024 Corporate and Clinical Highlights:
Phase 2 results from SHIMMER study in DLB showed strong clinical results – up to 91% slowing compared to placebo – across measures of behavior, function, cognition and movement after 6 months of zervimesine treatment.
Results shared in an archived webcast available on the IR webpage or directly by visiting https://lifescievents.com/event/cogrx/.
Results were also presented in January 2025 at the International Lewy Body Dementia Conference (ILBDC) by study director, James E Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine.
Results from Phase 2 SHINE study in Alzheimer's disease showed a near-total preservation of cognition (via ADAS-Cog11 and MMSE scales) in a population of zervimesine-treated Alzheimer's patients who had lower p-tau217 levels.
Results of this analysis were presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference by principal investigator, Michael Woodward, MD, associate professor, head of dementia research at Austin Health in Melbourne, Australia.
Reported a positive outcome of a masked analysis, referred to as a 'futility analysis,' of the Phase 2 MAGNIFY study of zervimesine in patients with geographic atrophy secondary to dry age-related macular degeneration (dry AMD). Along with published preclinical results, this supports the utility of zervimesine in the treatment of dry AMD.
Developed a novel chemical process for the manufacture of zervimesine as part of the Company's Phase 3 readiness plan. Provisional patent applications covering this chemical process have been filed.
Published six manuscripts in 2024, including final clinical results from the COG0105 SNAP study, which evaluated oligomer displacement following a single dose of zervimesine; and the COG0202 SEQUEL study, which measured the impact of zervimesine treatment on synaptic activity through quantitative EEG.
Conducted 12 presentations in 2024 at six scientific and medical congresses including a podium presentation of results from the Phase 2 COG0201 SHINE of zervimesine in mild-to-moderate Alzheimer's patients at the Clinical Trials on Alzheimer's Disease (CTAD) meeting.
Recent EventsIn January 2025, we made the strategic decision to voluntarily conclude the Phase 2 MAGNIFY (COG2201) study to focus resources on our ongoing programs in Alzheimer's and DLB. The early conclusion of MAGNIFY was not the result of any safety concerns. This pipeline prioritization has resulted in cost savings that are expected to extend the company's cash runway.
2024 Financial Results Cash and cash equivalents as of December 31, 2024, were approximately $25.0 million, and total obligated grant funds remaining from the NIA were $50.0 million.
Research and development expenses were $41.7 million for the year ended December 31, 2024, compared to $37.2 million for 2023. The increase was primarily related to higher costs associated with activities underway to complete two Phase 2 trials.
General and administrative expenses were $12.3 million for the year ended December 31, 2024, compared to $13.5 million for 2023. The decrease was primarily related to lower equity-based compensation and professional fees, partially offset by higher employee compensation and benefits.
The Company reported a net loss of $34.0 million, or $(0.86) per basic and diluted share for the year ended December 31, 2024, compared to a net loss of $25.8 million, or $(0.86) per basic and diluted share for 2023.
Conference Call Information Management will host a conference call and live webcast to discuss Cognition's financial results today at 8:00 a.m. ET. To participate in the conference call, dial (877) 704-4453 (U.S.) or (201) 389-0920 (international) and provide conference ID number 13751938. Alternatively, you may connect to the live webcast via this link: https://viavid.webcasts.com/starthere.jsp?ei=1709298&tp_key=d22af20c47 or by visiting the Investor Relations page of the Cognition website at www.cogrx.com. An archived webcast recording will be available approximately one hour after the conclusion of the live call.
About Cognition Therapeutics, Inc. Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We currently are investigating our lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer's disease, including the ongoing START study (NCT05531656) in early Alzheimer's disease. We believe zervimesine and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases that are functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at https://cogrx.com.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference call, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to statements related to our cash runway; our clinical studies of zervimesine (CT1812) and any analyses of the results therefrom; any expected or implied clinical benefits of zervimesine; the expectation that initial clinical results observed with zervimesine will be replicated in later trials; and our clinical development plans, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'seek,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'forecast,' 'potential' or 'continue' or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of global political changes and global economic conditions, supply chain and labor force; our ability to maintain our listing on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the 'Risk Factors' section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.Cognition Therapeutics, Inc.Unaudited Selected Financial Data
(in thousands, except share and per share data amounts)
For the Year Ended December 31,
Consolidated Statements of Operations Data:
2024
2023
Operating Expenses:
Research and development
$
41,676
$
37,196
General and administrative
12,290
13,528
Total operating expenses
53,966
50,724
Loss from operations
(53,966
)
(50,724
)
Other income (expense):
Grant income
19,549
24,805
Other income, net
666
158
Interest expense
(25
)
(27
)
Loss on currency translation from liquidation of subsidiary
(195
)
--
Total other income, net
19,995
24,936
Net loss
$
(33,971
)
$
(25,788
)
Foreign currency translation adjustment, including reclassifications
195
4
Total comprehensive loss
$
(33,776
)
$
(25,784
)
Net loss per share:
Basic
$
(0.86
)
$
(0.86
)
Diluted
$
(0.86
)
$
(0.86
)
Weighted-average common shares outstanding:
Basic
39,730,148
30,029,087
Diluted
39,730,148
30,029,087
As of
(in thousands)
December 31, 2024
December 31, 2023
Consolidated Balance Sheet Data:
Cash and cash equivalents
$
25,009
$
29,922
Total assets
30,234
35,163
Total liabilities
11,484
10,689
Accumulated deficit
(175,160
)
(141,189
)
Total stockholders equity
18,750
24,474
Contact Information: Cognition Therapeutics, Inc. info@cogrx.com
Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com
Mike Moyer (investors)LifeSci Advisorsmmoyer@lifesciadvisors.com
This press release was published by a CLEAR® Verified individual.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Velocity Trader Exposes Wall Street's Hidden Friday Price Strategy Used to Trigger Short-Term Market Wins
Jim Fink Investing's Velocity Trader system reveals how weekly options expiration patterns may create consistent, short-term price setups for traders seeking three- to ten-day market opportunities. New York, Aug. 04, 2025 (GLOBE NEWSWIRE) -- In today's volatile financial markets, retail investors face growing uncertainty—yet one reclusive former attorney has quietly built a decades-long strategy to exploit a pattern that appears every week: Friday market manipulation. With a verified 97.62% win rate across nearly a thousand closed trades, Jim Fink's Velocity Trader system is now revealing how short-term options pricing—crafted by institutional firms—may be used to pinpoint profitable market movements in just 3 to 10 days. This press release breaks down the method, the mechanics, and the mindset behind this low-time commitment trading system. Amid turbulent markets and the erosion of traditional investment confidence, more Americans are searching for alternative trading strategies that offer not only short-term potential—but consistent, repeatable results. Enter Jim Fink, a former Wall Street-connected attorney who turned a modest $50,000 trading account into multi-million-dollar gains using what he describes as a 'Tuesday-to-Friday' market anomaly. Today, after nearly a decade in relative anonymity, Fink is opening up about how options expiration cycles may be silently shaping price movements across the U.S. stock market—and how retail traders can follow along without needing professional tools, complex training, or hours in front of a screen. To learn how this unique Tuesday-to-Friday trading method works, and discover how it identifies weekly expiration patterns hidden in plain sight. Many of these signals are delivered directly to members each Tuesday, offering the potential for trades to play out by that Friday—or the Friday after. Those interested in a low-effort, research-based approach can and see how the system adapts to today's unpredictable market. Disclaimer: This article is for informational and educational purposes only. It does not constitute financial advice, investment guidance, or an offer to buy or sell any securities. Trading in the stock or options markets involves substantial risk, and individuals should perform their own due diligence or consult with a qualified advisor before making financial decisions. Past performance is not indicative of future results. This content may include references to a subscription-based research service; results are not guaranteed, and testimonials reflect individual experiences which may not be typical. Always invest responsibly. Why Interest in 'Short-Term Options Trading' Is Surging in 2025 The 2025 market environment has been marked by volatility, uncertainty, and sharp reversals—conditions that have left many traditional investors feeling sidelined. With interest rates holding steady after a turbulent cycle of hikes, and inflation concerns weighing heavily on growth sectors, the appeal of long-term buy-and-hold strategies has faded for a large portion of retail traders. In its place, a growing segment of individual investors are exploring short-term options trading strategies designed for faster, more frequent results. Search data from Google Trends shows a sharp increase in search volume for phrases like 'weekly options strategy,' 'Tuesday to Friday trades,' and 'short-term market moves,' particularly during earnings seasons and high-volatility periods. On platforms like Reddit's r/options and r/WallStreetBets, active discussions often center around low-time commitment systems that aim to deliver returns within three to ten days—especially ones designed to navigate institutional behavior during options expiry. This shift in retail sentiment has not gone unnoticed. Financial content creators on YouTube and X (formerly Twitter) are increasingly focused on breakdowns of market anomalies surrounding Friday expirations, with many users reporting experiments in replicating these phenomena with mixed results. Enter Jim Fink's Velocity Trader system—built specifically to operate within this emerging window of opportunity. Rather than attempting to outsmart macroeconomic cycles or predict quarterly earnings, the system focuses on an observable price pattern that recurs every week: a surge or drop in specific equities tied to the expiration of options contracts. These weekly moves—while seemingly chaotic on the surface—follow a deeper, more structured rhythm that Fink believes can be detected, measured, and traded. The market's increased appetite for transparency, autonomy, and fast-cycle trading has made systems like Velocity Trader more appealing in 2025 than ever before. While not intended as a replacement for broader portfolio strategies, this type of approach caters to investors seeking precision-guided tactics for capturing market inefficiencies—without needing to be glued to a screen all day or navigating complex software platforms. From self-directed retirees to part-time traders and financially savvy professionals, the demand for short-horizon, research-driven systems has fueled growing curiosity around strategies like Fink's—especially those that target market behavior over hype, and use timing patterns over forecasts to generate consistent entry points. Velocity Trader as a Response to This Shift As mainstream investing becomes more turbulent, the need for a reliable, low-commitment trading approach has never been greater. Velocity Trader was designed specifically to address this gap—offering a structured way to engage with short-term market movements without requiring technical expertise, real-time monitoring, or exposure to long-term downturns. At the center of this approach is Jim Fink, a former attorney who began experimenting with options trading during his lunch breaks. Working at a law firm that handled major Wall Street clients, Fink had a front-row view of institutional behavior. Over time, he developed a system that could identify patterns in the options market—patterns he believed were not random, but engineered to benefit large firms during the expiration cycle. Rather than try to predict market direction broadly, Fink's strategy zeros in on how specific stocks behave in the days leading up to options expiration. By focusing on Tuesday as the optimal entry point and Friday as the common settlement point, he built a rhythm that aligned with Wall Street's weekly cash flows—and began using that rhythm to place precision-timed trades. The result is a system that takes only minutes to execute, requires no constant screen time, and has shown a high degree of consistency over time. Importantly, it avoids holding stocks outright, sidestepping the risks of long-term market exposure. Instead, Velocity Trader uses a rules-based framework to identify option contracts that may benefit from short-term price movement, allowing investors to participate in potential gains without the typical guesswork. It's this blend of simplicity and strategy that makes Velocity Trader stand out in 2025. With so many investors searching for an alternative to passive portfolios and unpredictable tech swings, Fink's time-tested method offers a way to engage the market without relying on hype, headlines, or speculation. By removing complexity and focusing on repeatable outcomes, Velocity Trader positions itself not as a magic bullet—but as a serious tool for traders seeking clarity in an otherwise noisy environment. For those looking to explore how this system works in real time, to learn more about the weekly trade alerts and how they are delivered. Inside the Velocity Trader Platform: How the System Delivers Weekly Trade Setups Without Daily Screen Time Velocity Trader isn't a course, a classroom, or a coaching program—it's a streamlined system designed to deliver two new trade recommendations every Tuesday morning, directly to members, with the goal of capturing movement triggered by Wall Street's massive Friday options expirations. Each recommendation is structured to play out over a three- to ten-day period, depending on market conditions. This approach is radically different from day trading or trend following. Jim Fink's methodology doesn't rely on technical indicators, chart patterns, or fast-paced decisions. Instead, it begins with a core insight: many of the price movements seen near the end of each week are not random. They're driven by how institutional options contracts are structured—and how those firms need prices to move to remain profitable by Friday. Each Tuesday, members receive a detailed briefing on two targeted opportunities. These alerts are delivered by email (with optional text message support) and include: The exact option ticker symbol Entry price guidance A simple two-sentence summary of why the trade was chosen A ready-made phrase members can read to their broker (ideal for those who prefer placing trades over the phone) Fink also records a brief weekly video explaining the logic behind each recommendation, providing greater transparency without overwhelming users with jargon or technical analysis. These videos are designed for clarity and accessibility—even complete beginners can follow along. One of the most unique aspects of Velocity Trader is its time efficiency. According to Fink, each weekly setup takes no more than ten minutes to execute. There's no need to monitor price swings throughout the day. Once the trades are placed on Tuesday, the system is designed to let the week unfold—with many trades reaching their payout window by that Friday or the next. To better understand how these alerts are structured—and why they're built around Friday market cycles—visit the official Velocity Trader platform here and see how Jim Fink packages institutional insight into a simplified weekly delivery system. What Online Users Are Saying About This Category Across financial forums and content platforms, short-term options trading has become one of the most discussed strategies of 2025. Retail investors, side hustlers, and former long-term stock pickers are increasingly shifting attention to time-sensitive trades that operate on a weekly rhythm. But while the appetite for fast results is growing, so is the confusion around how to make it work without gambling or constant screen time. On Reddit threads like r/options and r/financialindependence, users often share anecdotal wins and losses, trading screenshots, or quick takes on 'what worked this week.' The sentiment is usually split between curiosity and skepticism. Many first-time traders express frustration over not knowing when to enter or exit a position. Others cite timing errors or poor options contract selection as barriers to consistency. In the YouTube and podcast world, creators are experimenting with weekly trade challenges, documenting their attempts to turn $500 into $1,000 in a few days using expiration-based setups. While some have posted occasional gains, few offer the structure or repeatability needed to scale the results. Comment sections are filled with questions about risk exposure, contract types, and how to avoid being 'burned' by surprise reversals. Amid this cultural conversation, there's growing interest in trade systems that simplify execution. Investors are looking for frameworks that do more than just share watchlists or theory—they want straightforward instructions, delivered at the right moment, that take into account how the broader market is behaving. This is where Velocity Trader has captured attention. By focusing not on hype or momentum, but on a fixed weekly entry point and a known institutional pressure pattern, Velocity Trader stands apart from most of what's trending online. It doesn't ask members to decode charts, monitor alerts around the clock, or chase breakouts after the fact. Instead, it gives them a blueprint for action each Tuesday—with the goal of walking away by Friday with a clean exit. For traders exploring how to cut through the noise and build a structured, low-guesswork routine, and see what a research-first, rhythm-based system looks like in action. Who Might Gravitate Toward This Product in 2025 Not every investor is looking for long-term compounding or dividend yield. In 2025, a growing segment of the retail market is motivated by flexibility, precision, and the ability to navigate short windows of volatility. While no single system fits every profile, Velocity Trader has drawn interest from several distinct types of market participants. Many subscribers come from professional backgrounds where time is limited. They're business owners, engineers, lawyers, and consultants—individuals who don't have hours to spend analyzing charts or watching CNBC, but still want a method to participate in market gains. The appeal lies in a process that can be executed in minutes on a lunch break or between client meetings, without the need for daily supervision. Another group includes retirees and pre-retirees aiming to build supplemental income without depleting their savings. For them, the idea of holding long-term positions through downturns can feel increasingly risky. The ability to target short-term setups—while using only capital they're comfortable putting to work—offers a sense of control and rhythm. Fink's strategy has also resonated with financially curious learners—people who may have dabbled in stocks or ETFs before, but never ventured into options. The educational aspect of Velocity Trader, particularly the weekly trade rationale videos and the eight-part foundational seminar, gives these users a sense of clarity. They're not just getting alerts—they're learning how a strategy fits together. It's worth emphasizing that this isn't a program designed for aggressive speculation or guaranteed results. Investors who gravitate toward Velocity Trader are typically those seeking structure. They value consistency over hype, and they prefer a rules-based system to intuition or social media-driven trends. They understand that no system is perfect, but they're looking for a way to remove guesswork from the equation. Those exploring whether a structured, weekly system aligns with their goals can to see how the alerts, schedule, and trade philosophy are delivered in practice. Market Category Reflections – Why This Niche Is Expanding In the ever-evolving world of personal finance, one category that has seen sharp growth is the niche of structured short-term trading systems. This expansion is driven by a combination of shifting investor expectations, widespread access to digital brokerages, and a broader skepticism toward long-horizon strategies that often fail to deliver during economic downturns. Historically, short-term trading was reserved for professionals with Bloomberg terminals and direct exchange access. But over the past five years, retail platforms have unlocked access to tools once limited to institutional desks. As a result, more investors are seeking frameworks that leverage this access while reducing exposure to constant volatility. Options contracts—especially weekly expirations—now provide a tactical entry point for traders who want flexibility without a full-time commitment. The emergence of market anomalies around Friday expirations has also drawn attention. Dozens of independent research threads, forum posts, and academic whitepapers have noted that certain equities exhibit unusual movement during the week's final sessions. Whether the result of institutional hedging or options contract pressure, the visibility of these patterns has opened the door for systems that can identify and act on them—like the one used by Velocity Trader. In parallel, key phrases such as 'weekly income strategies,' 'options trading for part-timers,' and '3-day trade opportunities' are climbing in Google search rankings. This suggests a strong and growing interest in approaches that favor agility over accumulation, and responsiveness over passive positioning. As financial content creation grows on platforms like YouTube, Substack, and podcasting networks, more attention is being paid to strategy-based systems with defined rules. Programs like Velocity Trader offer a counterbalance to personality-driven investing advice—emphasizing process over personal brand, and execution over commentary. For those watching the expansion of this niche closely, it's clear that the market is maturing. Structured short-term systems are no longer fringe—they are becoming a defined category within the broader trading landscape. To see how one such system operates in real-time, and explore the research principles behind its weekly timing approach. Public Debate – Supporters, Skeptics, and the Signals Behind the Buzz Any strategy that challenges conventional investing wisdom is bound to generate debate—and Velocity Trader is no exception. As news of Jim Fink's 97.62% historical win rate continues to circulate among traders and analysts, the public conversation around weekly options systems has become increasingly vocal. Supporters point to Fink's track record as a rare example of consistency in an unpredictable environment. They appreciate the system's structure: two trades a week, placed at the same time, with a defined logic tied to options expiration pressure. To many, this rhythm offers a sense of control in a market otherwise driven by noise, volatility, and unexpected macroeconomic headlines. Others view the system with skepticism, not because of the results, but because of how unusual the premise is. The idea that price movements may be partially driven by the institutional structure of options contracts—rather than earnings, sentiment, or news—is a provocative assertion. Some financial professionals argue that these patterns may be coincidental, or that they could disappear over time if too many traders begin to exploit them. Still, a growing segment of independent analysts and forum contributors are beginning to document and validate the existence of weekly price compression near expiration. Some refer to it as 'max pain theory,' while others point to institutional hedging behavior as the cause. Regardless of the term used, there is increasing consensus that a subset of short-term price moves are not as random as they once seemed. Meanwhile, in private groups and member communities, Fink's followers continue to post their feedback—sometimes cautiously optimistic, other times enthusiastically supportive. While the system does not promise results, its appeal lies in how it reframes the market itself: not as a chaotic ecosystem to be predicted, but as a series of engineered conditions to be tracked and reacted to. For a deeper look at how this conversation is unfolding and what makes the Velocity Trader system different from other weekly alert services, and see how the strategy is designed to adapt—not predict. About Jim Fink Investing Jim Fink Investing is a research-first platform focused on helping self-directed traders explore time-efficient options strategies grounded in institutional market patterns. The company's flagship service, Velocity Trader, was created to offer structure, transparency, and accessibility to individuals interested in participating in short-term opportunities without requiring constant screen time or advanced trading knowledge. Founded on the belief that market behavior often reflects engineered systems rather than randomness, Jim Fink's methodology emphasizes consistency over speculation. His work centers on identifying repeatable patterns tied to options expiration events—particularly those that occur during weekly Friday settlement cycles. While the strategy does not promise specific results and carries risk like all forms of investing, it offers a framework built around repeatable entry timing, clear trade rationale, and defined trade durations. Education plays a key role in the brand's identity. Velocity Trader members receive access to video briefings, simplified trade instructions, and a full training curriculum designed to demystify the options process. These tools are crafted to empower both new and experienced traders who want to take a structured approach to short-horizon positioning. The company does not manage client funds or provide individualized investment advice. Instead, it operates as a publishing and research organization, offering analysis, tools, and timely alerts for those interested in applying the strategy independently. To learn more about the platform's approach to rhythm-based trading and its commitment to educational access, for additional details. Contact Jim Fink Investing - Velocity Trader Email: CustomerService@ Phone: (202) 978‑3606 Website: DisclaimerThis press release is for informational purposes only. The content herein does not constitute financial, legal, or medical advice. Velocity Trader is not intended to diagnose, treat, predict, or guarantee any result or outcome. Individual experiences may vary, and outcomes are not assured. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. All statements made about product features, platform strategies, or training content reflect publicly available information, user discussions, or historical trends, and are not endorsed or validated by regulatory bodies. Please perform your own research before making financial, technological, or purchasing decisions. CONTACT: Email: CustomerService@ Phone: (202) 978‑3606Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Florida officials warn about risks of raw milk after 21 people sickened
The Florida Department of Health is warning about the risks of drinking raw, unpasteurized milk after 21 people, including six children under the age of 10, were sickened by E. coli and campylobacter bacteria linked to raw milk from the same farm. Seven people have been hospitalized, and two have developed severe complications. "Sanitation practices in this farm are of particular concern due to the number of cases," the department said in a news release. Officials did not identify the farm, but indicated its products were available in Northeast and Central Florida. CBS News has reached out to the health department for more information. Although it is illegal to sell raw milk for human consumption in Florida, it can be sold in the state if it's labeled as a pet food. Raw milk has been promoted by online wellness influencers and raw food advocates, boosting sales in recent years, but public health officials say it can be risky. The Food and Drug Administration and the Centers for Disease Control and Prevention say raw milk can carry life-threatening bacteria, such as E. coli, campylobacter, listeria or salmonella. These can cause symptoms including diarrhea, vomiting and stomach cramps. Severe cases can result in a condition called hemolytic uremic syndrome, or HUS, which can lead to kidney failure. Since 1987, 143 outbreaks have been linked to raw milk or raw milk products, some involving miscarriages, stillbirths, kidney failure and even deaths, according to the FDA. Pasteurization — a process of heating the milk — kills these bacteria. Pasteurization is required by federal law for any milk sold across state lines. Some individual states also restrict or ban the sale of raw milk, but others allow it. In an interview with CBS News Miami earlier this year, Mark McAfee, founder of one of the world's largest raw milk producers and head of an advocacy group called the Raw Milk Institute, claimed raw milk offers health benefits such as bioactives that boost the immune system. McAfee sells his raw milk legally in California, where no state law prohibits its sale. But the CDC says such claims are unfounded. "Pasteurized milk offers the same nutritional benefits without the risks of raw milk consumption," the agency says. The Florida Department of Health noted in its statement that "many people consume raw milk safely." But it also advised, "Floridians should be aware of potential risks associated with consumption, which may vary depending on the source of producer's handling of raw milk and milking procedures are vital in prevention of contamination." How safe is our Social Security safety net? Texas House votes to arrest lawmakers who fled state to stop redistricting vote What is "most-favored nation" drug pricing and how does it work? Solve the daily Crossword
Business Wire
2 hours ago
- Business Wire
Millrose Properties, Inc. Announces Pricing of Upsized $1.25 Billion Senior Notes Offering
MIAMI--(BUSINESS WIRE)--Millrose Properties, Inc. (NYSE: MRP) ('Millrose' or the 'Company') announced today the pricing of its private offering (the 'Offering') of $1.25 billion aggregate principal amount of its 6.375% Senior Notes due 2030 (the 'Notes'), representing a $250 million upsize from the previously announced offering size, at an initial offering price of 100.000% of the principal amount plus accrued interest, if any, from August 7, 2025. The Offering is expected to close on August 7, 2025, subject to customary closing conditions. Millrose intends to use the net proceeds of the Offering (i) to repay $500 million principal amount outstanding under the Company's term loan credit agreement, dated June 24, 2025 and maturing June 23, 2026, (ii) to repay $450 million principal amount of outstanding borrowings under the Company's revolving credit agreement dated February 7, 2025, and (iii) for general corporate purposes. The Notes and the related guarantee will be offered and sold only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended, (the 'Securities Act') and to certain non-U.S. persons in transactions outside the United States in reliance on Regulation S under the Securities Act. The Notes and the related guarantee have not been and will not be registered under the Securities Act or the securities laws of any state or other jurisdiction, and the Notes may not be offered or sold in the United States without registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities or blue sky laws and foreign securities laws. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This notice is being issued pursuant to and in accordance with Rule 135c under the Securities Act. About Millrose Properties, Inc. Millrose purchases and develops residential land and sells finished homesites to home builders by way of option contracts with predetermined costs and takedown schedules. Millrose serves as a solution for home builders seeking to expand access to finished homesites while implementing an asset-light strategy. As fully developed homesites are sold by Millrose, capital is recycled into future land acquisitions for home builders, providing customers with durable access to community growth. Forward-looking Statements Certain statements contained in this press release and oral statements made regarding the matters addressed in this release constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements about the Offering, the expected use of proceeds therefrom and other future events. All forward-looking statements included in this release are qualified in their entirety by, and should be read in the context of, the risk factors and other factors disclosed in the Company's filings with the Securities and Exchange Commission, which can be obtained free of charge on the Securities and Exchange Commission's web site at Except to the extent required by applicable law, Millrose undertakes no obligation to update or revise any information contained in this communication beyond the date hereof, whether as a result of new information, future events or otherwise.
